Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) EBIT (2020 - 2026)

Bioventus filings provide 6 years of EBIT readings, the most recent being $19.5 million for Q4 2025.

  • On a quarterly basis, EBIT rose 152.97% to $19.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.0 million, a 455.22% increase, with the full-year FY2025 number at $54.0 million, up 455.22% from a year prior.
  • EBIT hit $19.5 million in Q4 2025 for Bioventus, up from $11.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $22.0 million in Q2 2021 to a low of -$126.8 million in Q4 2022.
  • Median EBIT over the past 5 years was $1.8 million (2023), compared with a mean of -$9.9 million.
  • Biggest five-year swings in EBIT: crashed 12014.52% in 2022 and later soared 561.2% in 2024.
  • Bioventus' EBIT stood at -$3.2 million in 2021, then crashed by 396.41% to -$15.6 million in 2022, then soared by 107.45% to $1.2 million in 2023, then soared by 561.2% to $7.7 million in 2024, then skyrocketed by 152.97% to $19.5 million in 2025.
  • The last three reported values for EBIT were $19.5 million (Q4 2025), $11.3 million (Q3 2025), and $18.4 million (Q2 2025) per Business Quant data.